| Literature DB >> 29229998 |
Niamh M C Connolly1, Pierre Theurey2, Vera Adam-Vizi3, Nicolas G Bazan4, Paolo Bernardi2,5, Juan P Bolaños6, Carsten Culmsee7, Valina L Dawson8,9,10,11,12, Mohanish Deshmukh13, Michael R Duchen14, Heiko Düssmann1, Gary Fiskum15,16, Maria F Galindo17, Giles E Hardingham18, J Marie Hardwick19, Mika B Jekabsons20, Elizabeth A Jonas21, Joaquin Jordán22, Stuart A Lipton23,24,25, Giovanni Manfredi26, Mark P Mattson27, BethAnn McLaughlin28, Axel Methner29, Anne N Murphy30, Michael P Murphy31, David G Nicholls32, Brian M Polster15,16, Tullio Pozzan2,5, Rosario Rizzuto2,5, Jorgina Satrústegui33, Ruth S Slack34, Raymond A Swanson35, Russell H Swerdlow36, Yvonne Will37, Zheng Ying38, Alvin Joselin34, Anna Gioran39, Catarina Moreira Pinho40, Orla Watters1, Manuela Salvucci1, Irene Llorente-Folch1, David S Park34, Daniele Bano39, Maria Ankarcrona40, Paola Pizzo2,5, Jochen H M Prehn41.
Abstract
Neurodegenerative diseases are a spectrum of chronic, debilitating disorders characterised by the progressive degeneration and death of neurons. Mitochondrial dysfunction has been implicated in most neurodegenerative diseases, but in many instances it is unclear whether such dysfunction is a cause or an effect of the underlying pathology, and whether it represents a viable therapeutic target. It is therefore imperative to utilise and optimise cellular models and experimental techniques appropriate to determine the contribution of mitochondrial dysfunction to neurodegenerative disease phenotypes. In this consensus article, we collate details on and discuss pitfalls of existing experimental approaches to assess mitochondrial function in in vitro cellular models of neurodegenerative diseases, including specific protocols for the measurement of oxygen consumption rate in primary neuron cultures, and single-neuron, time-lapse fluorescence imaging of the mitochondrial membrane potential and mitochondrial NAD(P)H. As part of the Cellular Bioenergetics of Neurodegenerative Diseases (CeBioND) consortium ( www.cebiond.org ), we are performing cross-disease analyses to identify common and distinct molecular mechanisms involved in mitochondrial bioenergetic dysfunction in cellular models of Alzheimer's, Parkinson's, and Huntington's diseases. Here we provide detailed guidelines and protocols as standardised across the five collaborating laboratories of the CeBioND consortium, with additional contributions from other experts in the field.Entities:
Mesh:
Year: 2017 PMID: 29229998 PMCID: PMC5864235 DOI: 10.1038/s41418-017-0020-4
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828
Proteins/genes known to be mutated in Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS)
| Disease | Protein ( |
|---|---|
| AD | Amyloid precursor protein ( |
| Apolipoprotein E | |
| Microtubule associated protein tau ( | |
| Presenilin ( | |
| PD | α-synuclein ( |
| DJ-1 ( | |
| Leucine-rich repeat kinase 2 ( | |
| Parkin ( | |
| PTEN-induced kinase 1 ( | |
| FTD | Microtubule associated protein tau ( |
| HD | Huntingtin ( |
| ALS | Superoxide Dismutase ( |
| DNA/RNA binding protein Fused in Sarcoma ( | |
| (TAR)-DNA-binding protein 43 ( | |
| C9orf72 ( | |
| Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 ( |
Several of these genes (PSEN1/2; SNCA, DJ-1, LRRK2, Parkin, PINK-1; MAPT; Htt; SOD1, FUS, TARDP, and CHCHD10) encode proteins that regulate mitochondrial homeostasis and function to varying degrees [3, 5, 18, 19]. Listed genes are commonly targeted in transgenic animal models—see http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-actions/animal-and-cell-models/, http://www.alzforum.org/research-models, [190, 191], and references therein for further details. The ALS-associated genes FUS, TARDBP, C9orf72 and CHCHD10 are also associated with FTD
Fig. 1Immunofluorescent labelling and fluorescent images of cortical neurons prepared from post-natal wild-type mice
a After 10 days in vitro (DIV), cultures were stained with antibodies against the neuron-specific NF200 (red) and the astrocyte-specific GFAP (green), and with the DNA dye Hoechst (blue). Even when moved to a serum-free media quickly after dissociation, neuronal cultures contain a small proportion of astrocytes and other cell types (such as fibroblasts and endothelial cells). Neurons can be morphologically identified when performing single-cell experiments [153], but regular and careful characterisation of cultures is important for cell population assays. b Cortical neurons (after 6 DIV) transfected with a mitochondrial red fluorescent protein highlight the intricate mitochondrial network throughout the neuron
Fig. 2Schematic of standard experimental protocol to investigate the contribution of components of the mitochondrial respiratory chain to the oxygen (O2) consumption rate (OCR).
a Mitochondrial function can be thoroughly investigated in intact cells by measuring the OCR during sequential addition of mitochondrial respiratory inhibitors (marked with grey triangles). The different stages of the experiment (i)–(iv) and the measured parameters (a)–(f) are described in Protocol 1. The addition of pharmacological compounds or fuel substrates prior to oligomycin (not shown here) can capture further detail regarding the OCR. b Illustration of the effects of relevant pharmacological compounds on the mitochondrial respiratory chain, proton (H+) leak across the mitochondrial inner membrane, and the F1Fo ATP synthase, during the experimental stages marked as (i)–(iv) in A. O2 in the mitochondria is consumed by the respiratory chain through the activity of Complex IV. (i) In the basal state, mitochondrial O2 consumption is predominantly driven by H+ flux through the F1Fo ATP synthase. (ii) Inhibition of the F1Fo ATP synthase with oligomycin reduces mitochondrial O2 consumption, with the OCR in this phase predominantly driven by the H+ leak (but also by substrate oxidation). (iii) Addition of an uncoupler such as FCCP or CCCP increases the H+ leak across the inner membrane, creating a H+ short circuit and facilitating the measurement of maximal OCR. The optimal FCCP/CCCP concentration to induce maximal respiration should be determined for each experimental setting (details in Protocol 1), and it is advisable to also assess maximal respiratory capacity in the absence of oligomycin. (iv) Inhibition of respiratory chain activity with Rotenone and/or Antimycin A ablates mitochondrial O2 consumption. Any O2 consumption measured in this phase is due to non-mitochondrial O2 consumption. Rot rotenone, AA antimycin A, Oligo oligomycin, H+ proton, IMS intermembrane space. *Respiration in stage (b) is predominantly driven by H+ leak, but also by substrate oxidation
Drugs targeting the mitochondrial bioenergetic machinery
| Target | Drug | Concentrations (primary neurons) | Off-target effects |
|---|---|---|---|
| Complex I inhibition | Rotenone | 1–2 μM | Microtubules |
| Complex II inhibition | 3-NP | 0.1–1 mM | |
| Complex III inhibition | Antimycin A | 1–3 μM | Aspecific permeabilisation of the inner mitochondrial membrane |
| Stigmatellin | 1–3 μM | Also inhibits Complex I at high concentrations | |
| Myxothiazol | 1–5 μM | Also inhibits Complex I at high concentrations | |
| Complex IV inhibition | Cyanide (NaCN, KCN) | 1–5 mM | Haem-containing enzymes; formation of thiocyanate adducts |
| Sodium Azide | 1–5 mM | Interacts with active groups from catalase and nitrogen-based structures | |
| F1Fo ATP Synthase inhibition | Oligomycin | 1–5 μg/ml | |
| (1–6 μM)a | |||
| Protonophore (increases proton leak; uncouples mitochondria) | FCCP | High: 10 μM | |
| Low: 0.3–1 μM | |||
| CCCP | High: 10 μM | Inhibits lysosomes and autophagy | |
| Low: 0.3–1 μM | |||
| DNP | Low: 0.1–0.5 mM |
aOligomycin concentrations are often listed as μg/ml, as commercial preparations are a mixture of compounds with different individual molecular weights
Concentrations are guidelines only for primary neurons, and should be optimised for each cell type or experimental setting. Changes to the experimental buffer, such as the inclusion of bovine serum albumin, can alter some of the effective drug concentrations by more than four-fold [40, 44]. High protonophore concentrations collapse the mitochondrial membrane potential (and may also depolarise the plasma membrane potential [62]), while low concentrations induce maximal respiration (this requires titration to determine the optimal concentration for each experimental set-up [36, 37]). References for concentrations were obtained from experiments in primary neurons: [53, 64, 102, 153, 154, 192–194]
3-NP 3-nitropropionic acid, FCCP carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, CCCP carbonyl cyanide m-chlorophenylhydrazone, DNP 2,4-dinitrophenol
Fig. 3Representative images and time-series data from TMRM (10 nM) measurements in wild-type mouse cortical neurons exposed to mitochondrial inhibitors
. a Brightfield and TMRM fluorescence images were captured on a Zeiss Axiovert 100 microscope (brightfield and TMRM fluorescence are merged in the left-most image, TMRM only in the other images). b Time-series TMRM fluorescence measurements within the region of interest marked by the white polygon in (A)(ii). The precise time-points of the images in (A) are marked (i)–(iii) on the graph. Baseline fluorescence was recorded for 10 min pre-treatment and used to normalise the signal. Complex III inhibition with antimycin A (1 μM) induced a decrease in TMRM fluorescence, indicating mitochondrial membrane depolarisation. Subsequent oligomycin addition (2 μg/ml) further reduced TMRM fluorescence, indicating that prior to oligomycin addition the mitochondrial membrane potential was being maintained by the F1Fo ATP synthase operating in reverse. The loss of any remaining TMRM fluorescence after FCCP addition (10 μM) indicates mitochondrial membrane potential collapse
Fig. 4Representative images and time-series data from NAD(P)H autofluorescence measurements in wild-type mouse cortical neurons exposed to mitochondrial inhibitors
a Brightfield and NAD(P)H autofluorescence images were captured on a Zeiss Axiovert 100 microscope. b Time-series autofluorescence measurements from the region of interest marked within a white polygon in (A)(iii). The precise time-points of the images in (A) are marked (i)-(iv) on the graph. Baseline fluorescence was recorded for 5 min pre-treatment and used to normalise the signal. Inhibition of the F1Fo ATP synthase with oligomycin (2 μg/ml) reduced NADH consumption by the respiratory chain, leading to an increase in the autofluorescence signal. Subsequent mitochondrial uncoupling with FCCP (0.5 μM) increased respiratory NADH oxidation, decreasing autofluorescence
Description of spectrophotometric enzymatic assays to measure respiratory complex activity
| Respiratory complex (synonyms) | Enzymatic assay description |
|---|---|
| Complex I (NADH:ubiquinone oxidoreductase, NADH dehydrogenase, EC 1.6.5.3) | In catalysing the oxidation of NADH to NAD+, Complex I transfers electrons from NADH to ubiquinone (coenzyme Q10). Assays to measure Complex I activity therefore utilise NADH as the electron donor, and a ubiquinone analogue (e.g. coenzyme Q1 or decylubiquinone, DB) as the electron acceptor. Activity is determined by measuring the rate of oxidation of NADH to NAD+, or less frequently by measuring the rate of reduction of the ubiquinone analogue. The rate of NADH oxidation is measured by tracking the decrease in absorbance of the sample at 340 nm, or DB reduction can be followed at 247–272 nm. The majority of Complex I activity should be rotenone-sensitive. |
| Complex II (succinate-ubiquinone oxidoreductase, succinate dehydrogenase) | Complex II oxidises succinate to fumarate, while reducing ubiquinone to ubiquinol. In this assay, succinate is used as the electron donor with dichlorophenolindophenol (DCPIP) the electron acceptor. Complex II activity can be measured by following the decrease in absorbance at 600 nm caused by the reduction of DCPIP. Complex II activity should be sensitive to malonate. Rotenone and antimycin A are usually added to minimise the endogenous ubiquinone accepting electrons from Complex II (and the resultant underestimation of Complex II activity). |
| Complex III (ubiquinol-cytochrome | In catalysing the reduction of cytochrome |
| Combined complex I and complex III (NADH-cytochrome | The rate of reduction of cytochrome |
| Combined complex II and III (succinate-cytochrome | The rate of reduction of cytochrome |
| Complex IV (cytochrome | Complex IV transfers electrons from cytochrome |
| F1Fo ATP synthase | The activity of the F1Fo ATP synthase (assayed as the reverse ATPase activity) is more difficult to measure, due to a high level of oligomycin-resistant ATPase activity [ |
Protocols for a variety of assays can be found on manufacturers’ websites for commercially available assays (e.g. the MitoToxTM suite from MitoSciences, or MitoCheck® from Cayman), and in various publications (e.g. [43, 57, 94]). Respiratory chain complex activities can be normalised to the amount of protein in the sample, or to citrate synthase activity [43, 57].
Fig. 5mitoATeam, a FRET-based reporter of mitochondrial ATP, can be transfected into primary neurons
[99] a The reporter comprises a linker protein (ε-subunit of a bacterial F1Fo ATP synthase) inserted between a donor CFP and acceptor YFP (enhanced CFP and Venus). ATP binding induces a conformational change in the linker protein, increasing FRET between the two FPs and altering the emitted fluorescence. Ratiometric measurements are obtained by calculating the FRET ratio (CFP/YFP). The acceptor YFP can also be laser-excited at ~488 nm. Fluorescent emissions from both FPs should be monitored, to ensure that any ratio change is due to altered FRET (opposite changes in the fluorescence of the individual FPs), rather than other sources (such as increased auto-fluorescence). Image reproduced with permission from [12]. b Representative images of primary mouse cortical neurons (DIV8) transfected with mitoATeam, stained with TMRM, and imaged on a Zeiss LSM 710 confocal microscope. Mitochondrial localisation of the mitoATeam probe was verified by colocalisation with the TMRM signal (merged TMRM and Mito-ATeam image). Scale bar = 10 μm. DIC differential interference contrast
Genetically encoded fluorescent reporters of ATP that have been successfully targeted to neuronal mitochondria
| Reporter name | Reporter detail | Excitation/emission wavelengths (nm) | Dissociation constant ( | References |
|---|---|---|---|---|
| mitoATeam (mitAT1.03) | CFP-YFP | CFP (mECFP): 435/475 | 3.3 | [ |
| FRET | YFP (cpVenus): 515/527 | |||
| Mit GO-ATeam 2 | GFP-OFP | GFP (mEGFP): 470/510 | 2.3 | [ |
| FRET | OFP (mKOk): 550/560 |
Publications refer to the work that originally generated the probe and studies where the probe was utilised in neuronal mitochondria
Several genetically encoded fluorescent and bioluminescent reporters of Ca2+ with varying affinities (Kd) that have been successfully targeted to neuronal mitochondria
| Reporter name | Reporter detail | Excitation, emission wavelengths (nm) | Dissociation constant, | References |
|---|---|---|---|---|
| Rhod-2 | Fluorescent molecule | 0.6* | [ | |
| 4mtD2cpv | Yellow cameleon (FRET) | CFP (ECFP): | 4mtD2cpv: 0.1, 7.7 | [ |
| 4mtD3cpv | YFP (cp173Venus): | 4mtD3cpv: 0.76 | ||
| 4mtD4cpv | 4mtD4cpv: 49.7 | |||
| mtAEQmut | Aequorin (bioluminescence) | Varying affinities [ | [ | |
| Mit-GEM-GECO-1 | Single FP, dual emission, ratiometric | 0.34 | [ | |
| Mito-LAR-GECO1.2 | Single FP (RFP) | 12 | [ | |
| mito-GCaMP2 | Single FP (cpEGFP) | 0.2 | [ | |
| mt-RCaMP | Single FP (cp-mRuby) | 1.6 | [ | |
| mtPericam | Dual-excitation, ratiometric | 1.7 | [ | |
Publications refer to the work that originally generated the probe and/or studies where the probe was utilised in neuronal mitochondria. Multiple mitochondria-localised Ca2+ reporters based on GCaMP have been generated
aRhod-2 analogues have varying affinities
Genetically encoded fluorescent reporters of pH that have been successfully targeted to neuronal mitochondria
| Reporter name | Reporter type | Excitation, emission wavelength (nm) | p | References |
|---|---|---|---|---|
| MIMS-EYFP | Single FP (EYFP) | ~7.0 | [ | |
| mt-EYFP, mito-EYFP | Single FP (EYFP) | ~7.0 | [ | |
| mitoSypHer | Single FP (cpYFP), dual-excitation, ratiometric | ~8.7 | [ | |
| mtAlpHi | Single FP (EYFP) chimera | ~8.5 | [ | |
Publications refer to the work that originally generated the probe and studies where the probe was utilised in neuronal mitochondria. See text for more details
Fluorescent reporters of reactive oxygen species (ROS) that have been successfully targeted to neuronal mitochondria
| Reporter name | Reporter type | Peak excitation, emission wavelengths (nm) | References |
|---|---|---|---|
| mito-Het | Fluorescent molecule | [ | |
| MitoSOX Red | |||
| MitoPY1 | Fluorescein/rhodamine fluorescent molecule | [ | |
| mito-roGFP | Single FP (dual-excitation, ratiometric) | ||
| roGFPm | [ | ||
| Mito-Grx1-roGFP2 | Single FP (dual-excitation, ratiometric) | [ | |
These reporters do not have absolute specificity for any single ROS type, and the accurate measurement of mitochondria-derived ROS is associated with various drawbacks, as outlined in the text. Publications refer to the work that originally generated the probe and/or studies where the probe was utilised in neuronal mitochondria